Dr. Jonathan Shoag

New research led by investigators from Weill Cornell Medicine, Fred Hutchinson Cancer Center, University Hospitals Cleveland and Case Western Reserve University found that prostate cancer screening with the prostate specific antigen (PSA) blood test has remarkably favorable tradeoffs.

The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, say investigators at Weill Cornell Medicine, NewYork-Presbyterian, University of Washington School of Medicine and the Fred Hutchinson Cancer Research Center.

Dr. Jonathan Shoag, a urologic oncology fellow and instructor of urology at Weill Cornell Medicine, has been named a winner of this year’s prestigious Damon Runyon Physician-Scientist Training Award.